Share This Author
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
- S. Verstovsek, H. Kantarjian, +10 authors A. Tefferi
- The New England journal of medicine
- 15 September 2010
INCB018424 was associated with marked and durable clinical benefits in patients with myelofibrosis for whom no approved therapies existed, and clinical benefits were associated with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myel ofibrosis. Expand
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
- M. Keating, S. O'brien, +12 authors H. Kantarjian
- Journal of clinical oncology : official journal…
- 20 June 2005
FCR produced a high CR rate in previously untreated CLL, and most patients had no detectable disease on flow cytometry at the end of therapy. Expand
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
Lenalidomide can reduce transfusion requirements and reverse cytologic and cytogenetic abnormalities in patients who have the myelodysplastic syndrome with the 5q31 deletion. Expand
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
It is concluded that decitabine is effective in myeloid malignancies, and low doses are as or more effective than higher doses. Expand
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
Inotuzumab ozogamicin shows promise as a treatment for refractory and relapsed ALL and was expressed in more than 50% of blasts in all patients. Expand
Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia
The current analysis updated the long‐term results with the original hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD) program, with a median follow‐up time of 63 months. Expand
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Modification of the hyper-CVAD regimen with anthracycline intensification did not improve outcome, and other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease. Expand
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
A weighted prognostic model, or nomogram, predictive for overall survival was constructed using the following independent characteristics: age, beta-2 microglobulin, absolute lymphocyte count, sex, Rai stage, and number of involved lymph node groups to help patients and clinicians in clinical decision making as well as in clinical research and clinical trial design. Expand
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Outcome with hyper-CVAD and imatinib mesylate appears better than with prior regimens; continued accrual and longer follow-up of the current cohort is needed. Expand
Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia
Adult Burkitt‐type lymphoma (BL) and acute lymphoblastic leukemia (B‐ALL) are rare entities composing 1% to 5% of non‐Hodgkin lymphomas NHL) or ALL. Prognosis of BL and B‐ALL has been poor with… Expand